Literature DB >> 7605397

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection.

Gail Shor-Posner1, Abdul Basit2, Ying Lu2, Claudio Cabrejos2, Jeani Chang2, Maryann Fletcher3, Emilio Mantero-Atienza1, Marianna K Baum1.   

Abstract

PURPOSE: Patients with the acquired immunodeficiency syndrome exhibit marked disturbances in lipid metabolism. Because altered lipid metabolism may affect immune processes, this study characterized the lipid profile of asymptomatic individuals infected with the human immunodeficiency virus (HIV-1), in relationship to immune function. PATIENTS AND METHODS: Serum levels of triglycerides and cholesterol were determined in 94 asymptomatic HIV-1-infected (Centers for Disease Control stage II, III) homosexual men and 42 healthy seronegative control subjects. Immune assessment included measurements of lymphocyte subpopulations (CD4), immune activation (beta 2-microglobulin), natural killer cell function, and lymphocyte proliferation in response to mitogens phytohemagglutinin and pokeweed. Dietary intake was determined using a semiquantitative food frequency questionnaire.
RESULTS: Despite greater consumption of saturated fat and cholesterol, significantly lower levels of total, high-density, and low-density lipoprotein cholesterol were observed in HIV-1-seropositive men, relative to seronegative controls (p < 0.05), with 40% of the HIV-1-infected group demonstrating hypocholesterolemia (less than 150 mg/dL). Low values of total, high-density, and low-density cholesterol were associated with elevated levels of beta 2-microglobulin in HIV-1-seropositive men. No difference between the groups was noted for serum triglycerides. HIV-1-infected subjects did not demonstrate the significant inverse relationship between cholesterol and mitogen response observed in seronegative controls.
CONCLUSIONS: These findings indicate that low levels of cholesterol are prevalent during the early stages of HIV-1 infection and associated with specific alterations in immune function, suggesting that hypocholesterolemia may be a useful marker of disease progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7605397     DOI: 10.1016/0002-9343(93)90087-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  50 in total

1.  Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Madhu N Rao; Grace A Lee; Carl Grunfeld
Journal:  Am J Infect Dis       Date:  2006-09-30

Review 2.  Managing the metabolic and morphologic complications of HIV.

Authors:  M Keith Rawlings; Guillermo Santos
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

Review 3.  Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?

Authors:  David Nolan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus.

Authors:  Olamide D Jarrett; Christine A Wanke; Robin Ruthazer; Ioana Bica; Rita Isaac; Tamsin A Knox
Journal:  AIDS Patient Care STDS       Date:  2013-05       Impact factor: 5.078

5.  Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania.

Authors:  Catharina Armstrong; Enju Liu; James Okuma; Donna Spiegelman; Chalamilla Guerino; Marina Njelekela; Steve Grinspoon; Wafaie Fawzi; Claudia Hawkins
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

Review 6.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

7.  Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women.

Authors:  Kathryn Anastos; François Ndamage; Dalian Lu; Mardge H Cohen; Qiuhu Shi; Jason Lazar; Venerand Bigirimana; Eugene Mutimura
Journal:  AIDS Res Ther       Date:  2010-08-26       Impact factor: 2.250

8.  Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study.

Authors:  María Jose Míguez; John E Lewis; Vaughn E Bryant; Rhonda Rosenberg; Ximena Burbano; Joel Fishman; Deshratn Asthana; Rui Duan; Nair Madhavan; Robert M Malow
Journal:  J Int AIDS Soc       Date:  2010-07-13       Impact factor: 5.396

9.  Antiretroviral compounds and cholesterol efflux from macrophages.

Authors:  Nigora Mukhamedova; Honor Rose; Huanhuan L Cui; Angela Grant; Urbain Tchoua; Anthony Dart; Michael Bukrinsky; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2009-03-21       Impact factor: 5.162

10.  New options in the treatment of lipid disorders in HIV-infected patients.

Authors:  Erika Ferrari Rafael da Silva; Giuseppe Bárbaro
Journal:  Open AIDS J       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.